Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
... should seek immediate medical attention.
patient information and/or full
prescribing information, visit ... and seek medical attention right away.
patient information ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... few patients required treatment.
prescribing information, please visit ... erythromycin, and phenytoin. (Please see full
Prescribing Information for other potential drug ... For more detailed study information, please see full
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
... When this percentage is extrapolated to the full
US population aged 18 and over, approximately 9.8 ...
Additional information about VYVANSE and full
Prescribing Information, including the Medication ... . Additional information about ADDERALL XR and full
Prescribing Information, including the Medication ...
Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity
... of mixed nuts and half portion of muffin; or 3) full
portion of muffin. Each snack accounted for 450 ... with heart heath. The findings revealed that the full
dose nut group had significantly reduced LDL and total cholesterol levels compared to the full
dose muffin group, as well as a significant ...
Kensey Nash Announces IDE Submission for Cartilage Repair Device
... an important accomplishment towards achieving full
commercialization of this proprietary product and ... blood products. The Company has also developed a full
complement of specialized color-coded instruments ... for the third quarter of fiscal 2009 and the full
year fiscal 2009. The Company has tried to ...
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
... for adult patients with refractory AA in 1999 and full
approval in March 2005 for refractory AA, ie, ... Regarding EU Labeling for TEMODAL
prescribing information for TEMODAL can be found ... in the first cycle, respectively.
prescribing information for TEMODAR can be found ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... warfarin, erythromycin and phenytoin. (Please see full
Prescribing Information for other potential drug ... For more detailed study information please see full
About Tasigna ... with hepatic impairment.
Please see full
About Exjade ...
PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
... PLCSF) announced today that it has received full
approval from the U.S. Food and Drug ... of PLC, said, "We are very pleased with the FDA's full
approval to the Investigational Device Exemption ... under the CE Mark we received in late 2007. full
FDA approval of the IDE supplement is another ...
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
... warfarin, erythromycin
and phenytoin. (Please see full
Prescribing Information for other potential
drug ... more detailed study information, please see full
(**)For more detailed study information, please see full
AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
... for use alone or with
other treatments. See full
Prescribing Information under the section ... For more information about CASODEX, including full
Information please visit ... For more information about ZOLADEX, including full
Information for ZOLADEX 3.6 mg Depot ...
Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
... updates on Zingo launch progress,
announced the full
enrollment of its Phase 3 Adlea clinical trials ... year and in 2009. The company anticipates
automation of Zingo manufacturing will decrease ... procedures in children ages
three to 18. For full
Zingo prescribing information and other ...
GeoVax Reports Progress on Its AIDS Vaccine Technology
... virus). In
Phase 1 trials, both 1/10th dose and full
dose of the GeoVax vaccine
elicited anti-HIV T-cells, whereas the full
dose was required to elicit
good frequencies of ... base of safety and immunogenicity data
for the full
dose of the GeoVax AIDS vaccine with a view to ...
FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
... convert an accelerated
approval indication into full
approval. It is based on a ... (see PRECAUTIONS, Laboratory Tests, in full
information for CD25 expression ... Visual Loss
For detailed safety information and full
prescribing information about
ONTAK (denileukin ...
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
... First Presentation of full
Data Set from the TRIUMPH-1 Trial of Inhaled ... viable treatment options
for patients along the full
continuum of this life-threatening disease,"
said ... at the University of Michigan, presented the full
data set from the
TRIUMPH-1 study of ...
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
... Technology enabled administration of a full
monthly dose via a
single site to patients with ... the amount of enzyme
required to enable a full
monthly dose to be infused in a single site ... of Immune Globulin Intravenous
prescribing information, please visit
Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
... of certain
milestones. Revenue for the full
year of 2007 was $1.5 million as compared
to $1.7 ... The increases in both the
fourth quarter and full
year of 2007 as compared to 2006 were due to ... year. General and
administrative costs for the full
year of 2007 were $14.0 million compared
to $11.3 ...
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
... for the comparable period in
2006. For the full
year of 2007, the Company recorded a net loss ... financial information is shown below. GeoVax's full
audited financial statements are included ... 2006, is designed to evaluate results from full
dose administration of GeoVax HIV/AIDS vaccines. ...
RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
... than Restylane volume was required
to reach full
correction in this split-face trial comparative ... and at three months in order to achieve full
correction. The paper
published in the Journal of ... required significantly less
material to achieve full
correction, with an average total injection ...
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
... 2008, Gilead is
not making any adjustments to the full
year 2007 Product Revenue guidance
provided on ... didanosine-associated adverse events. See full
for complete list of ... to update any such
U.S. prescribing information, including Boxed ...
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
... didanosine-associated adverse events. See U.S. full
Information for complete list of ... to update any such forward-looking statements.
U.S. prescribing information, including Boxed ... available at http://www.atripla.com .
U.S. prescribing information for SUSTIVA is ...
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
... 2006, is designed to evaluate results from full
dose administration of GeoVax HIV/AIDS ... data indicates excellent safety in this full
dose trial with immune response data from the ... immune responses) at both low (1/10th) dose and full
doses. * GeoVax vaccines were well ...
Vanda Pharmaceuticals Reports Third Quarter 2007 Results
... Phase II Proof of Concept Trial; Updates full
Year 2007 Financial Guidance
ROCKVILLE, Md., ... 2006. FINANCIAL GUIDANCE Vanda is updating its full
year 2007 financial guidance as a result ... of the VEC-162 trial in primary insomnia. full
results are now expected to show ...
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
... statistically significant findings even after a full
Anti-Nicotine Antibody Levels Drive ... reduction in cigarettes smoked over the full
12 months compared
to placebo (p * Using a ... which will drive continuous abstinence out to a full
we know the relationship between the ...
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
... week one that were observed throughout the full
treatment period. At
endpoint, VYVANSE provided a ... years. Additional information about VYVANSE and full
are available at ... survey of adults aged 18 to 44, projected
to the full
U.S. adult population. ADHD is a neurobiological ...
Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
... September 28. Immediately, UPMC
was able to make full
use of the new system and the center now is treating
on average three patients, with full
course treatments, per day. Gamma Knife(R) ... the
Leksell Gamma Knife. UPMC continues to use a full
range of Elekta stereotactic systems
including a ...
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
... didanosine-associated adverse events. See full
for complete list of ... which the Company incorporates by reference. full
U.S. prescribing information for ATRIPLA is available at
http://www.atripla.com . full
U.S. prescribing information for SUSTIVA is ...
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
... didanosine-associated adverse events. See full
for complete list of ... update any such forward-looking statements. U.S. full
prescribing information for ATRIPLA is available at
http://www.ATRIPLA.com . U.S. full
prescribing information for SUSTIVA is available ...
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
... U.S. Food and Drug
Administration (FDA) granted full
(traditional) approval of Aptivus(R)
(tipranavir) ... and had documented PI resistance. At the time of full
approval, the studies examined treatment ... innovative therapies for HIV patients. The full
APTIVUS further demonstrates our ...
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
... and/or impaired hepatic/renal
function. (For full
information on dose modification see SPC.) ... cardiovascular risk.) Common: Chest pain. For full
details of these and other side-effects, please ... Injection site reactions (mainly
mild). For full
details of these and other side-effects, please ...
GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
... immune responses) at both low (1/10th) dose and full
doses. -- GeoVax vaccines were well tolerated ... trial participants. -- 80% of both the low and full
dose trial participants responded to the ... -- More volunteers had antibody responses to the full
dose than to the 1/10th dose vaccine, whereas ...
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
... for this disease." Pharmion expects to present full
study results at an upcoming medical
meeting. ... in this
press release will be confirmed upon full
analysis of the results of the
Vidaza Survival ... even if these topline
results are confirmed upon full
analysis of the study, we cannot guarantee
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
... of a co-
stimulatory signal required for full
T-cell activation. About Juvenile Idiopathic ... tract infection, sore throat, and nausea. For full
Prescribing Information, please visit ... of people treated
with placebo. According to the full
prescribing information, the most
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... and CFO of Isis.
Upcoming Key Milestones
data from a Phase 3 study evaluating mipomersen in homozygous Familial ... We have the technology, the expertise and the momentum to realize the full
potential of antisense as a drug discovery technology," concluded Ms. ...
SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
MUMBAI, India, Aug. 5 /PRNewswire/ -- SIRO Clinpharm, a global, full
service Contract Research Organization (CRO) founded in India, today ... one of the leading global Clinical Research Organizations (CROs), offering full
scope services, conducting clinical trials in the pharmaceutical, ...
Is Your Hair Taking a Break?
... a short growth phase, resulting in baby fine hairs that do not reach their full
length or diameter.
Fortunately, several treatment options are ... growth phase of hair -- providing more time for hair to grow out to its full
"Minoxidil is a wonderful option for women with thinning ...
July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
... care to confirm a diagnosis and start treatment, which can up the odds of full
The disorder is often related to a viral infection. ... Lyme disease or diabetes.
Treatment increases the likelihood of full
recovery and may help shorten the recovery time. A doctor may prescribe a ...
FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
... Schwalm, President of Eisai Inc. "This application is one part of a full
complement of clinical development programs we have committed for Dacogen ... and diarrhea (34 percent).
Please visit www.dacogen.com for full
About Eisai Corporation of North America ...
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
Please visit http://www.asacol.com/pdf/us-asacol.pdf for Asacol full
Prescribing Information and http://www.AsacolHD.com for Asacol HD full
About Procter & Gamble (NYSE: PG ) ...
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
... (five percent or greater) were headache, nausea, dizziness, and insomnia. full
prescribing information for NUVIGIL is available at www.NUVIGIL.com . ... [C-II]. The company also markets numerous products internationally. full
prescribing information on its U.S. products is available at ....
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
... been used by more than one million patients since its introduction. For full
prescribing information, visit www.BYETTA.com .
Important Safety ... about any side effect that is bothersome or does not go away. For full
prescribing information, visit www.BYETTA.com .
About Amylin and ...